Stock Track | 10x Genomics Soars 11.54% After-Hours on Better-Than-Expected Q3 Results and Strong Q4 Outlook

Stock Track

Nov 07, 2025

Shares of 10x Genomics, Inc. (TXG) surged 11.54% in after-hours trading on Thursday, following the release of the company's third-quarter 2025 financial results that exceeded analyst expectations.

The life sciences technology company reported a Q3 earnings per share (EPS) of $(0.22), beating the estimated $(0.29). Revenue for the quarter came in at $149.002 million, surpassing the projected $142.490 million. Despite posting a net loss of $27.5 million, the company's performance showed significant improvement compared to expectations.

10x Genomics also impressed investors with a robust gross margin of 67% for the quarter. Looking ahead, the company provided an optimistic outlook for the fourth quarter, projecting revenue between $154 million and $158 million. This positive guidance, coupled with the better-than-anticipated Q3 results, appears to have fueled investor enthusiasm, driving the stock's significant after-hours rally.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1124717346"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1124717346\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1124717346?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 05:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1124717346","market":"sg","top_or_hot":-1,"title":"Stock Track | 10x Genomics Soars 11.54% After-Hours on Better-Than-Expected Q3 Results and Strong Q4 Outlook","media":"Stock Track","content":"<p>Shares of 10x Genomics, Inc. (TXG) surged 11.54% in after-hours trading on Thursday, following the release of the company's third-quarter 2025 financial results that exceeded analyst expectations.</p>\n\n<p>The life sciences technology company reported a Q3 earnings per share (EPS) of $(0.22), beating the estimated $(0.29). Revenue for the quarter came in at $149.002 million, surpassing the projected $142.490 million. Despite posting a net loss of $27.5 million, the company's performance showed significant improvement compared to expectations.</p>\n\n<p>10x Genomics also impressed investors with a robust gross margin of 67% for the quarter. Looking ahead, the company provided an optimistic outlook for the fourth quarter, projecting revenue between $154 million and $158 million. This positive guidance, coupled with the better-than-anticipated Q3 results, appears to have fueled investor enthusiasm, driving the stock's significant after-hours rally.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | 10x Genomics Soars 11.54% After-Hours on Better-Than-Expected Q3 Results and Strong Q4 Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | 10x Genomics Soars 11.54% After-Hours on Better-Than-Expected Q3 Results and Strong Q4 Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-07 05:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of 10x Genomics, Inc. (TXG) surged 11.54% in after-hours trading on Thursday, following the release of the company's third-quarter 2025 financial results that exceeded analyst expectations.</p>\n\n<p>The life sciences technology company reported a Q3 earnings per share (EPS) of $(0.22), beating the estimated $(0.29). Revenue for the quarter came in at $149.002 million, surpassing the projected $142.490 million. Despite posting a net loss of $27.5 million, the company's performance showed significant improvement compared to expectations.</p>\n\n<p>10x Genomics also impressed investors with a robust gross margin of 67% for the quarter. Looking ahead, the company provided an optimistic outlook for the fourth quarter, projecting revenue between $154 million and $158 million. This positive guidance, coupled with the better-than-anticipated Q3 results, appears to have fueled investor enthusiasm, driving the stock's significant after-hours rally.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TXG","symbol_name":"10x Genomics, Inc.","start_time":0,"source_url":"","article_id":"1124717346","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1124717346","pubTimestamp":1762464880,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of 10x Genomics, Inc. (TXG) surged 11.54% in after-hours trading on Thursday, following the release of the company's third-quarter 2025 financial results that exceeded analyst expectations....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TXG":"10x Genomics, Inc."},"translate_title":"个股追踪|10x Genomics盘后大涨11.54%，Q3业绩好于预期，Q4前景强劲","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TXG":1},"content_text":"Shares of 10x Genomics, Inc. (TXG) surged 11.54% in after-hours trading on Thursday, following the release of the company's third-quarter 2025 financial results that exceeded analyst expectations.\nThe life sciences technology company reported a Q3 earnings per share (EPS) of $(0.22), beating the estimated $(0.29). Revenue for the quarter came in at $149.002 million, surpassing the projected $142.490 million. Despite posting a net loss of $27.5 million, the company's performance showed significant improvement compared to expectations.\n10x Genomics also impressed investors with a robust gross margin of 67% for the quarter. Looking ahead, the company provided an optimistic outlook for the fourth quarter, projecting revenue between $154 million and $158 million. This positive guidance, coupled with the better-than-anticipated Q3 results, appears to have fueled investor enthusiasm, driving the stock's significant after-hours rally.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}